No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
RARE Ultragenyx Pharmaceutical
- 42.270
- -1.150-2.65%
Close Dec 30 16:00 ET
- 41.510
- -0.760-1.80%
Pre 06:42 ET
3.90BMarket Cap-6.66P/E (TTM)
43.820High41.530Low789.57KVolume43.020Open43.420Pre Close33.31MTurnover0.89%Turnover RatioLossP/E (Static)92.34MShares60.37052wk High11.25P/B3.77BFloat Cap37.02052wk Low--Dividend TTM89.11MShs Float179.647Historical High--Div YieldTTM5.27%Amplitude31.520Historical Low42.188Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $95
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Wells Fargo Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $88
Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Heat List
US
Overall
Symbol
Price
% Chg
No Data